ATE254450T1 - Aerosolzusammensetzungen - Google Patents
AerosolzusammensetzungenInfo
- Publication number
- ATE254450T1 ATE254450T1 AT96931227T AT96931227T ATE254450T1 AT E254450 T1 ATE254450 T1 AT E254450T1 AT 96931227 T AT96931227 T AT 96931227T AT 96931227 T AT96931227 T AT 96931227T AT E254450 T1 ATE254450 T1 AT E254450T1
- Authority
- AT
- Austria
- Prior art keywords
- liquefied hydrofluoroalkane
- fatty acid
- active ingredient
- medium
- chain fatty
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000005828 hydrofluoroalkanes Chemical class 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000004667 medium chain fatty acids Chemical class 0.000 abstract 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 2
- 238000001816 cooling Methods 0.000 abstract 1
- 239000002270 dispersing agent Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23934295 | 1995-09-19 | ||
PCT/JP1996/002670 WO1997010806A1 (en) | 1995-09-19 | 1996-09-18 | Aerosol compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE254450T1 true ATE254450T1 (de) | 2003-12-15 |
Family
ID=17043318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96931227T ATE254450T1 (de) | 1995-09-19 | 1996-09-18 | Aerosolzusammensetzungen |
Country Status (16)
Country | Link |
---|---|
US (2) | US6361760B1 (de) |
EP (1) | EP0851753B1 (de) |
JP (2) | JP3266005B2 (de) |
KR (1) | KR100523754B1 (de) |
CN (1) | CN1137680C (de) |
AT (1) | ATE254450T1 (de) |
AU (1) | AU719613B2 (de) |
CA (1) | CA2232378C (de) |
DE (1) | DE69630798T2 (de) |
DK (1) | DK0851753T3 (de) |
ES (1) | ES2206590T3 (de) |
HK (1) | HK1017845A1 (de) |
PT (1) | PT851753E (de) |
TW (1) | TW429153B (de) |
WO (1) | WO1997010806A1 (de) |
ZA (1) | ZA967887B (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998041191A1 (fr) * | 1997-03-14 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Preparation pour aerosol |
GB0012383D0 (en) * | 2000-05-22 | 2000-07-12 | Novartis Ag | Organic compounds |
US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
US6943267B1 (en) | 2001-08-24 | 2005-09-13 | Utah State University | Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases |
EP1525308A4 (de) * | 2002-05-30 | 2006-11-02 | Celgene Corp | Verfahren zur verwendung von jnk- oder mkk-inhibitoren zur modulation der zelldifferenzierung und zur behandlung von myeloproliferativen störungen und myelodysplastischen syndromen |
WO2004027027A2 (en) | 2002-09-18 | 2004-04-01 | Trustees Of The University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
AU2002952559A0 (en) * | 2002-11-08 | 2002-11-21 | Fujisawa Pharmaceutical Co., Ltd. | New use |
US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
US20050019366A1 (en) * | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
US20040230272A1 (en) * | 2003-04-11 | 2004-11-18 | Cates Adam W. | Subcutaneous lead with temporary pharmacological agents |
CA2528841A1 (en) * | 2003-06-10 | 2004-12-23 | Astellas Pharma Inc. | Aerosol preparation comprising enclosure enclosing aerosol composition containing macrolide compound |
US7585517B2 (en) * | 2003-09-18 | 2009-09-08 | Macusight, Inc. | Transscleral delivery |
BRPI0416266A (pt) * | 2003-11-06 | 2007-01-09 | Celgene Corp | método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente |
TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
CA2552305A1 (en) * | 2003-12-30 | 2005-07-14 | Astellas Pharma Inc. | Use of macrolides for treating or preventing airflow obstruction |
BRPI0518255A2 (pt) * | 2004-11-23 | 2008-11-11 | Celgene Corp | mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica |
DK1848431T3 (en) * | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
US8142781B2 (en) | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
US8124095B2 (en) * | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
JP5528708B2 (ja) | 2006-02-09 | 2014-06-25 | 参天製薬株式会社 | 安定な製剤ならびにそれらを調製および使用する方法 |
CN101443004B (zh) | 2006-03-23 | 2013-03-06 | 参天制药株式会社 | 用于与血管通透性有关的疾病或病症的制剂 |
US8759297B2 (en) * | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
US9044391B2 (en) * | 2007-01-10 | 2015-06-02 | Board Of Regents, The University Of Texas System | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
US20090011040A1 (en) * | 2007-05-02 | 2009-01-08 | Naash Muna I | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
CA2694762A1 (en) | 2007-07-27 | 2009-02-05 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
US20100098693A1 (en) * | 2008-10-07 | 2010-04-22 | Pardridge William M | Compositions and methods for blood-brain barrier delivery of organophosphatases |
NZ592861A (en) * | 2008-11-04 | 2013-01-25 | Cipla Ltd | Pharmaceutical aerosol composition |
EP2408474B1 (de) | 2009-03-18 | 2019-06-26 | Armagen, Inc. | Zusammensetzungen und verfahren zur verabreichung von igg-köderrezeptor-fusionsproteinen in die blut-hirn-schranke |
EP2485761B1 (de) | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Verfahren und zusammensetzungen für erhöhte iduronat-2-sulfatase-aktivität im zns |
DK2501716T3 (en) | 2009-11-19 | 2015-04-07 | Solis Biodyne Oü | Formations to increase polypeptidstabilitet and activity and related practices |
US20110318277A1 (en) * | 2010-06-25 | 2011-12-29 | APT Pharmaceuticals, Inc. University of Maryland, Baltimore | Tacrolimus compositions for aerosol administration |
WO2013081706A1 (en) | 2011-12-02 | 2013-06-06 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase a activity in the cns |
EP3024848B1 (de) | 2013-07-22 | 2020-07-08 | Armagen, Inc. | Verfahren und zusammensetzungen zur erhöhung der enzymaktivität im zns |
US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4894366A (en) * | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
GB8608080D0 (en) | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
US5540931A (en) | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
IE66485B1 (en) | 1989-07-05 | 1996-01-10 | Fujisawa Pharmaceutical Co | Aqueous liquid composition for external use |
US5215995A (en) | 1989-10-16 | 1993-06-01 | Fujisawa Pharmaceutical Co., Ltd. | Hair revitalizing agent |
PH31204A (en) | 1990-11-02 | 1998-05-05 | Fujisawa Pharmaceutical Co | Pharmaceutical composition. |
IE65341B1 (en) | 1990-11-08 | 1995-10-18 | Fujisawa Pharmaceutical Co | Suspensions containing tricyclic compounds |
WO1992008474A2 (en) * | 1990-11-20 | 1992-05-29 | The National Heart & Lung Institute | Treatment of lung diseases |
US5817333A (en) * | 1991-10-31 | 1998-10-06 | Fujisawa Pharmaceutical Co., Ltd. | Liposome preparation containing a tricyclic compound |
JP3520517B2 (ja) | 1992-11-18 | 2004-04-19 | 藤沢薬品工業株式会社 | 医薬用持続性製剤 |
JPH06345646A (ja) | 1993-06-08 | 1994-12-20 | Fujisawa Pharmaceut Co Ltd | ローション剤 |
US5635161A (en) * | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
US5681501A (en) * | 1995-10-11 | 1997-10-28 | E. I. Du Pont De Nemours And Company | Compositions including a hydrofluoropropane |
WO1998041191A1 (fr) * | 1997-03-14 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Preparation pour aerosol |
CN1259053A (zh) | 1997-04-11 | 2000-07-05 | 藤泽药品工业株式会社 | 药物组合物 |
-
1996
- 1996-09-18 JP JP24605396A patent/JP3266005B2/ja not_active Expired - Lifetime
- 1996-09-18 PT PT96931227T patent/PT851753E/pt unknown
- 1996-09-18 CA CA002232378A patent/CA2232378C/en not_active Expired - Fee Related
- 1996-09-18 ZA ZA967887A patent/ZA967887B/xx unknown
- 1996-09-18 EP EP96931227A patent/EP0851753B1/de not_active Expired - Lifetime
- 1996-09-18 CN CNB961981660A patent/CN1137680C/zh not_active Expired - Fee Related
- 1996-09-18 WO PCT/JP1996/002670 patent/WO1997010806A1/en active IP Right Grant
- 1996-09-18 DE DE69630798T patent/DE69630798T2/de not_active Expired - Lifetime
- 1996-09-18 JP JP51258997A patent/JP3362394B2/ja not_active Expired - Fee Related
- 1996-09-18 AU AU69998/96A patent/AU719613B2/en not_active Ceased
- 1996-09-18 DK DK96931227T patent/DK0851753T3/da active
- 1996-09-18 KR KR1019980701910A patent/KR100523754B1/ko not_active IP Right Cessation
- 1996-09-18 ES ES96931227T patent/ES2206590T3/es not_active Expired - Lifetime
- 1996-09-18 AT AT96931227T patent/ATE254450T1/de not_active IP Right Cessation
- 1996-09-18 US US09/029,863 patent/US6361760B1/en not_active Expired - Fee Related
- 1996-09-19 TW TW085111460A patent/TW429153B/zh not_active IP Right Cessation
-
1999
- 1999-05-07 HK HK99102062A patent/HK1017845A1/xx not_active IP Right Cessation
-
2001
- 2001-11-28 US US09/994,702 patent/US6524556B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
PT851753E (pt) | 2004-04-30 |
AU719613B2 (en) | 2000-05-11 |
CN1137680C (zh) | 2004-02-11 |
CN1201384A (zh) | 1998-12-09 |
ZA967887B (en) | 1997-04-07 |
US20020061906A1 (en) | 2002-05-23 |
US6361760B1 (en) | 2002-03-26 |
JP3266005B2 (ja) | 2002-03-18 |
KR19990044656A (ko) | 1999-06-25 |
DE69630798T2 (de) | 2004-09-23 |
JP3362394B2 (ja) | 2003-01-07 |
DE69630798D1 (de) | 2003-12-24 |
US6524556B2 (en) | 2003-02-25 |
TW429153B (en) | 2001-04-11 |
JP2000505050A (ja) | 2000-04-25 |
KR100523754B1 (ko) | 2007-06-04 |
ES2206590T3 (es) | 2004-05-16 |
DK0851753T3 (da) | 2004-03-15 |
AU6999896A (en) | 1997-04-09 |
JPH09143054A (ja) | 1997-06-03 |
WO1997010806A1 (en) | 1997-03-27 |
HK1017845A1 (en) | 1999-12-03 |
CA2232378C (en) | 2009-04-14 |
CA2232378A1 (en) | 1997-03-27 |
EP0851753A1 (de) | 1998-07-08 |
EP0851753B1 (de) | 2003-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69630798D1 (de) | Aerosolzusammensetzungen | |
ES2157307T3 (es) | Composicion topica que contiene un antagonista de sustancia p. | |
AR021922A1 (es) | Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol. | |
GB2062465B (en) | Topical preparation containing nitroglycerine and optionally other medicaments | |
ECSP920885A (es) | Sustrato de material para articulos para fumar | |
YU86001A (sh) | Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini | |
CA2105575A1 (en) | Esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions | |
MX9606501A (es) | Composiciones antifungosas y curativas para heridas y metodos para preparar y utilizar las mismas. | |
BR9805993A (pt) | Composição farmacêutica de aerosol. | |
KR930007444A (ko) | 4-비페닐아세트 산(bpaa)를 함유하는 제약학적 조성물 | |
MX9606502A (es) | Composiciones antiqueratoliticas y curativas para heridas y metodos para preparar y utilizar las mismas. | |
AR021921A1 (es) | Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos y budesonido. | |
JPS5659710A (en) | Preventive and remedy for psoriasis | |
MY118301A (en) | Local anesthetic for external use | |
AP2003002716A0 (en) | Medicinal compositions containing propenone derivatives. | |
DK0693926T3 (da) | Ny farmaceutisk sammensætning til fremstilling af et stabilt pulver indeholdende en kombination af acetylsalicylsyre og metoclopramid som aktiv bestanddel. | |
SE9403389D0 (sv) | Pharmaceutical composition containing derivattves of sex hormones | |
AU8740198A (en) | Inhibitor and preservative formulation | |
EP0968713A4 (de) | Isosorbidnitrat enthaltentende pflaster | |
EP0966958A4 (de) | Aerosol-präparation | |
WO1996001128A3 (de) | Niedrig dosierte steroidtabletten, die gallussäureester als antioxidans enthalten, verfahren zur herstellung und die verwendung | |
ES456094A1 (es) | Un procedimiento para la preparacion de 2-acetoxi-benzoato de 2-(carbamoil) fenilo. | |
AU528211B2 (en) | Synergistic analgesic compositions of suprofen | |
JPS5762220A (en) | Embrocation for external use | |
KR910016314A (ko) | 항생활성 성분의 치과용 국소지속성 투여조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0851753 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |